Hmdb loader
Record Information
Version5.0
StatusDetected but not Quantified
Creation Date2021-09-11 11:44:34 UTC
Update Date2021-09-26 23:06:29 UTC
HMDB IDHMDB0253331
Secondary Accession NumbersNone
Metabolite Identification
Common NameIbritumomab tiuxetan
Description2-({2-[bis(carboxymethyl)amino]-3-{4-[(methyl-C-hydroxycarbonimidoyl)amino]phenyl}propyl}({2-[bis(carboxymethyl)amino]propyl})amino)acetic acid belongs to the class of organic compounds known as pentacarboxylic acids and derivatives. These are carboxylic acids containing exactly five carboxyl groups. Based on a literature review very few articles have been published on 2-({2-[bis(carboxymethyl)amino]-3-{4-[(methyl-C-hydroxycarbonimidoyl)amino]phenyl}propyl}({2-[bis(carboxymethyl)amino]propyl})amino)acetic acid. This compound has been identified in human blood as reported by (PMID: 31557052 ). Ibritumomab tiuxetan is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Ibritumomab tiuxetan is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources.
Structure
Thumb
Synonyms
ValueSource
2-({2-[bis(carboxymethyl)amino]-3-{4-[(methyl-C-hydroxycarbonimidoyl)amino]phenyl}propyl}({2-[bis(carboxymethyl)amino]propyl})amino)acetateGenerator
Chemical FormulaC24H35N5O11
Average Molecular Weight569.568
Monoisotopic Molecular Weight569.233306967
IUPAC Name2-({2-[bis(carboxymethyl)amino]-3-{4-[(methylcarbamoyl)amino]phenyl}propyl}({2-[bis(carboxymethyl)amino]propyl})amino)acetic acid
Traditional Name({2-[bis(carboxymethyl)amino]-3-{4-[(methylcarbamoyl)amino]phenyl}propyl}({2-[bis(carboxymethyl)amino]propyl})amino)acetic acid
CAS Registry NumberNot Available
SMILES
CNC(=O)NC1=CC=C(CC(CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1
InChI Identifier
InChI=1S/C24H35N5O11/c1-15(28(11-20(32)33)12-21(34)35)8-27(10-19(30)31)9-18(29(13-22(36)37)14-23(38)39)7-16-3-5-17(6-4-16)26-24(40)25-2/h3-6,15,18H,7-14H2,1-2H3,(H,30,31)(H,32,33)(H,34,35)(H,36,37)(H,38,39)(H2,25,26,40)
InChI KeyRTQWWZBSTRGEAV-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as pentacarboxylic acids and derivatives. These are carboxylic acids containing exactly five carboxyl groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassPentacarboxylic acids and derivatives
Direct ParentPentacarboxylic acids and derivatives
Alternative Parents
Substituents
  • Pentacarboxylic acid or derivatives
  • Alpha-amino acid
  • Alpha-amino acid or derivatives
  • Amphetamine or derivatives
  • N-phenylurea
  • Aralkylamine
  • Benzenoid
  • Monocyclic benzene moiety
  • Amino acid or derivatives
  • Amino acid
  • Urea
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid
  • Organic nitrogen compound
  • Organonitrogen compound
  • Carbonyl group
  • Organooxygen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Amine
  • Organic oxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Ontology
Not AvailableNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
logP-0.9ALOGPS
logP-4.6ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)2.1ChemAxon
pKa (Strongest Basic)9.47ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area237.35 ŲChemAxon
Rotatable Bond Count19ChemAxon
Refractivity138.34 m³·mol⁻¹ChemAxon
Polarizability55.07 ųChemAxon
Number of Rings1ChemAxon
BioavailabilityNoChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+213.55530932474
DeepCCS[M-H]-211.1630932474
DeepCCS[M-2H]-244.04230932474
DeepCCS[M+Na]+220.18430932474

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
Ibritumomab tiuxetanCNC(=O)NC1=CC=C(CC(CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C15456.3Standard polar33892256
Ibritumomab tiuxetanCNC(=O)NC1=CC=C(CC(CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C12902.5Standard non polar33892256
Ibritumomab tiuxetanCNC(=O)NC1=CC=C(CC(CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C14947.4Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Ibritumomab tiuxetan,1TMS,isomer #4CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O4845.5Semi standard non polar33892256
Ibritumomab tiuxetan,1TMS,isomer #4CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O4067.7Standard non polar33892256
Ibritumomab tiuxetan,1TMS,isomer #4CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O7722.1Standard polar33892256
Ibritumomab tiuxetan,2TMS,isomer #10CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O4713.9Semi standard non polar33892256
Ibritumomab tiuxetan,2TMS,isomer #10CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O3983.0Standard non polar33892256
Ibritumomab tiuxetan,2TMS,isomer #10CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O7175.2Standard polar33892256
Ibritumomab tiuxetan,2TMS,isomer #12CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O4580.1Semi standard non polar33892256
Ibritumomab tiuxetan,2TMS,isomer #12CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O4062.8Standard non polar33892256
Ibritumomab tiuxetan,2TMS,isomer #12CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O6772.9Standard polar33892256
Ibritumomab tiuxetan,2TMS,isomer #4CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C4709.3Semi standard non polar33892256
Ibritumomab tiuxetan,2TMS,isomer #4CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C3983.7Standard non polar33892256
Ibritumomab tiuxetan,2TMS,isomer #4CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C7177.1Standard polar33892256
Ibritumomab tiuxetan,2TMS,isomer #7CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O4707.7Semi standard non polar33892256
Ibritumomab tiuxetan,2TMS,isomer #7CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O3976.6Standard non polar33892256
Ibritumomab tiuxetan,2TMS,isomer #7CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O7167.1Standard polar33892256
Ibritumomab tiuxetan,3TMS,isomer #11CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C4448.6Semi standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #11CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C4010.5Standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #11CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C6358.2Standard polar33892256
Ibritumomab tiuxetan,3TMS,isomer #13CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O4597.5Semi standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #13CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O3934.3Standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #13CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O6706.8Standard polar33892256
Ibritumomab tiuxetan,3TMS,isomer #15CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O4458.6Semi standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #15CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O4008.7Standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #15CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O6343.8Standard polar33892256
Ibritumomab tiuxetan,3TMS,isomer #16CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O4607.4Semi standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #16CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O3939.6Standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #16CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O6708.0Standard polar33892256
Ibritumomab tiuxetan,3TMS,isomer #18CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O4453.2Semi standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #18CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O4008.7Standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #18CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O6357.7Standard polar33892256
Ibritumomab tiuxetan,3TMS,isomer #3CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C4594.7Semi standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #3CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C3936.1Standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #3CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C6707.5Standard polar33892256
Ibritumomab tiuxetan,3TMS,isomer #6CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C4607.1Semi standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #6CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C3938.5Standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #6CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C6708.2Standard polar33892256
Ibritumomab tiuxetan,3TMS,isomer #9CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C4600.0Semi standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #9CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C3944.1Standard non polar33892256
Ibritumomab tiuxetan,3TMS,isomer #9CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C6720.1Standard polar33892256
Ibritumomab tiuxetan,4TMS,isomer #11CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C4391.8Semi standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #11CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C3966.8Standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #11CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C5985.9Standard polar33892256
Ibritumomab tiuxetan,4TMS,isomer #12CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C4508.2Semi standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #12CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C3928.6Standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #12CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C6308.5Standard polar33892256
Ibritumomab tiuxetan,4TMS,isomer #14CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C4385.8Semi standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #14CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C3974.9Standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #14CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C6005.4Standard polar33892256
Ibritumomab tiuxetan,4TMS,isomer #15CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O4512.4Semi standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #15CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O3923.3Standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #15CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O6291.0Standard polar33892256
Ibritumomab tiuxetan,4TMS,isomer #17CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O4387.0Semi standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #17CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O3970.2Standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #17CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O5987.7Standard polar33892256
Ibritumomab tiuxetan,4TMS,isomer #18CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O4391.0Semi standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #18CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O3967.9Standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #18CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O5986.6Standard polar33892256
Ibritumomab tiuxetan,4TMS,isomer #2CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C4507.9Semi standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #2CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C3923.1Standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #2CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C6290.2Standard polar33892256
Ibritumomab tiuxetan,4TMS,isomer #5CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C4498.3Semi standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #5CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C3928.0Standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #5CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O)CC(=O)O[Si](C)(C)C6307.7Standard polar33892256
Ibritumomab tiuxetan,4TMS,isomer #7CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C4385.4Semi standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #7CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C3972.0Standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #7CC(CN(CC(=O)O[Si](C)(C)C)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C5987.9Standard polar33892256
Ibritumomab tiuxetan,4TMS,isomer #9CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C4506.5Semi standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #9CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C3927.1Standard non polar33892256
Ibritumomab tiuxetan,4TMS,isomer #9CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C)N(CC(=O)O[Si](C)(C)C)CC(=O)O[Si](C)(C)C6307.4Standard polar33892256
Ibritumomab tiuxetan,1TBDMS,isomer #4CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O5061.1Semi standard non polar33892256
Ibritumomab tiuxetan,1TBDMS,isomer #4CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O4226.3Standard non polar33892256
Ibritumomab tiuxetan,1TBDMS,isomer #4CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O7457.2Standard polar33892256
Ibritumomab tiuxetan,2TBDMS,isomer #10CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C(C)(C)C)N(CC(=O)O)CC(=O)O5160.8Semi standard non polar33892256
Ibritumomab tiuxetan,2TBDMS,isomer #10CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C(C)(C)C)N(CC(=O)O)CC(=O)O4312.2Standard non polar33892256
Ibritumomab tiuxetan,2TBDMS,isomer #10CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O[Si](C)(C)C(C)(C)C)N(CC(=O)O)CC(=O)O6880.0Standard polar33892256
Ibritumomab tiuxetan,2TBDMS,isomer #12CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O5014.6Semi standard non polar33892256
Ibritumomab tiuxetan,2TBDMS,isomer #12CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O4338.2Standard non polar33892256
Ibritumomab tiuxetan,2TBDMS,isomer #12CC(CN(CC(=O)O)CC(CC1=CC=C(N(C(=O)N(C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O6604.0Standard polar33892256
Ibritumomab tiuxetan,2TBDMS,isomer #4CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C(C)(C)C5159.8Semi standard non polar33892256
Ibritumomab tiuxetan,2TBDMS,isomer #4CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C(C)(C)C4314.2Standard non polar33892256
Ibritumomab tiuxetan,2TBDMS,isomer #4CC(CN(CC(=O)O)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O[Si](C)(C)C(C)(C)C6880.8Standard polar33892256
Ibritumomab tiuxetan,2TBDMS,isomer #7CC(CN(CC(=O)O[Si](C)(C)C(C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O5157.0Semi standard non polar33892256
Ibritumomab tiuxetan,2TBDMS,isomer #7CC(CN(CC(=O)O[Si](C)(C)C(C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O4305.7Standard non polar33892256
Ibritumomab tiuxetan,2TBDMS,isomer #7CC(CN(CC(=O)O[Si](C)(C)C(C)(C)C)CC(CC1=CC=C(NC(=O)N(C)[Si](C)(C)C(C)(C)C)C=C1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O6870.9Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_1_1) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_1_2) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_1_3) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_1_5) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_1) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_2) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_3) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_5) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_6) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_8) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_9) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_2_11) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_1) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_2) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_4) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_5) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_7) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_8) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_10) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_12) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_14) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_3_17) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_4_1) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_4_3) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ibritumomab tiuxetan GC-MS (TMS_4_4) - 70eV, PositiveNot Available2021-11-04Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ibritumomab tiuxetan 10V, Positive-QTOFsplash10-0fki-0101490000-c5120fb01deefe11ea132021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ibritumomab tiuxetan 20V, Positive-QTOFsplash10-00di-0203690000-ce1ba21c6d250448ef072021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ibritumomab tiuxetan 40V, Positive-QTOFsplash10-0h6u-2902000000-cf452df02b42efbb8a102021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ibritumomab tiuxetan 10V, Negative-QTOFsplash10-014i-0000190000-f38e03beab61c949c76a2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ibritumomab tiuxetan 20V, Negative-QTOFsplash10-0596-0101890000-b1044e8538b1dfd1df002021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Ibritumomab tiuxetan 40V, Negative-QTOFsplash10-0a7l-3716910000-87d84bad4a0cf50f46c02021-10-12Wishart LabView Spectrum
Biological Properties
Cellular LocationsNot Available
Biospecimen Locations
  • Blood
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedNot SpecifiedNot SpecifiedNormal details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID35763218
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem Compound92002593
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Barupal DK, Fiehn O: Generating the Blood Exposome Database Using a Comprehensive Text Mining and Database Fusion Approach. Environ Health Perspect. 2019 Sep;127(9):97008. doi: 10.1289/EHP4713. Epub 2019 Sep 26. [PubMed:31557052 ]